Dickson, RumonaBoland, AngelaDuarte, RuiKotas, EleanorWoolacott, NerysHodgson, RobertRiemsma, RobGrimm, SabineRamaekers, BramJoore, ManuelaBüyükkaramikli, NasuhKaltenthaler, EvaStevenson, MattPandor, AbdullahEdwards, SteveHoyle, MartinShepherd, JonathanArmoiry, XavierBrazzelli, Miriam2019-02-062019-02-062018-08Dickson, R, Boland, A, Duarte, R, Kotas, E, Woolacott, N, Hodgson, R, Riemsma, R, Grimm, S, Ramaekers, B, Joore, M, Büyükkaramikli, N, Kaltenthaler, E, Stevenson, M, Pandor, A, Edwards, S, Hoyle, M, Shepherd, J, Armoiry, X & Brazzelli, M 2018, 'EMA and NICE Appraisal Processes for Cancer Drugs : Current Status and Uncertainties', Applied Health Economics and Health Policy, vol. 16, no. 4, pp. 429-432. https://doi.org/10.1007/s40258-018-0393-7PubMedCentral: PMC6028888http://hdl.handle.net/2164/11875The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.4418311engSDG 3 - Good Health and Well-beingH Social SciencesHJournal article10.1007/s40258-018-0393-7164